News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ACT Biotech Announces Treatment of First Gastric Cancer Patients with Telatinib in a Phase 2 Clinical Trial in the U.S. and Spain


7/30/2009 8:55:20 AM

SAN FRANCISCO--(BUSINESS WIRE)--ACT Biotech Inc., a privately held biotechnology company developing a portfolio of best-in-class oral kinase inhibitors as anti-cancer drugs, today announced the treatment of the first patients in a Phase 2 clinical trial of Telatinib in combination with standard-of-care chemotherapy for the treatment of gastric cancer. The Phase 2 multi-center trial is being conducted in the U.S. and in Spain with Principal Investigators at the University of Texas MD Anderson Cancer Center in Houston, Texas and the Vall d'Hebron University Hospital in Barcelona, Spain.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES